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Introduction
Thrombocytopenia is generally defined as platelet counts <150x10 9 /L and represents a common laboratory finding in intensive care unit (ICU) patients. Up to 50% of patients present with thrombocytopenia at some time point of their ICU stay, and 5-20% develop severe thrombocytopenia, defined as platelet counts <50x10 9 /L. [1] [2] [3] Normally, the platelet count in the peripheral blood is controlled by complex interactions regulating platelet production in the bone marrow, platelet pooling in the liver and spleen, and their elimination in the reticuloendothelial system, 4,5 which then feeds back into thrombopoietin regulation. 6 The platelet count is rather constant in an individual person. 7 In critically ill patients, however, these mechanisms can fail, which results in disturbance of the balance between platelet production, platelet pooling, and platelet consumption. Thrombocytopenia should be seen as a sensitive marker for considerable alteration of normal physiology. This is most likely the reason for the consistent finding that a low platelet count is associated with an increased risk for mortality in critically ill patients. [8] [9] [10] [11] [12] [13] [14] [15] For example, in a prospective observational study that analyzed 257 patients who stayed longer than two weeks in the ICU, platelets. 17, 18 (e.g. by hemolysins). 19 Table 1 correlates these mechanisms with potential underlying diseases in typical ICU patients.
A crucial step for successful treatment of thrombocytopenia in the critically ill is to identify the underlying cause(s) of the low platelet count, as management differs substantially depending on the underlying disease. While in patients with impaired platelet production, or increased platelet consumption/destruction, platelet transfusion might be indicated, this could be deleterious in patients with increased intravascular platelet activation like in heparininduced thrombocytopenia (HIT) or thrombotic thrombocytopenic purpura (TTP), 20, 21 and possibly in certain prothrombotic forms of disseminated intravascular coagulopathy (DIC). In the following we will discuss different causes for thrombocytopenia and the implications on patient management, using illustrative patient cases.
As with any complex disease, a detailed history and careful physical examination are key to achieving the right diagnosis. Supported by a few laboratory tests, interpretation of these data within the specific clinical context often enables diagnosis.
In case of unexpected thrombocytopenia, the first question should be whether the patient is really thrombocytopenic.
Case 1: Pseudothrombocytopenia

Scenario
A 67-year-old male patient who suffered from acute coronary syndrome (ACS) received emergency percutaneous coronary intervention with implantation of several stents, one of them in the left main coronary artery, followed by therapeutic dose anticoagulation with unfractionated heparin (UFH) plus platelet inhibition with aspirin, clopidogrel, and eptifibatide (all in standard doses). Six hours post-intervention, the platelet count had dropped from 270x10 9 /L (pre-procedure) to 6x10 9 /L (in ethylenediaminetetraacetic acid
[EDTA]-anticoagulated blood as well as in citrated blood), and the patient was admitted
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Management
The case raises several management issues: Should all antiplatelet drugs, including eptifibatide, be stopped? Should heparin be stopped? Should platelets be transfused to prevent bleeding? Should tranexamic acid be given prophylactically? As physical examination revealed no bleeding signs, immediate review of the blood film was requested, which showed large platelet aggregates, confirming the diagnosis of eptifibatide-induced pseudothrombocytopenia. The patient was transferred back to the cardiology ward for ongoing standard post-stenting treatment.
Comment
Pseudothrombocytopenia is a laboratory artifact usually caused by in vitro platelet agglutination in EDTA-anticoagulated blood. These platelet aggregates can not be recognized by automated cell counters, thus underestimating the true platelet count.
Naturally-occurring immunoglobulin class M antibodies directed against epitopes on platelet glycoprotein (GP) IIbIIIa, which are expressed upon calcium chelation by EDTA, 22, 23 cause in vitro platelet clumping, and spurious thrombocytopenia. In most cases, the diagnosis is confirmed by measuring normal platelet counts in citrated blood.
However, during treatment with GPIIbIIIa antagonists, pseudothrombocytopenia can also occur in citrated blood.
24
As GPIIbIIIa antagonists can induce both real thrombocytopenia as well as pseudothrombocytopenia in more than 3% of patients, 25,26 exclusion of pseudothrombocytopenia is crucial before any antiplatelet therapy is stopped or even prothrombotic treatments are initiated due to the high risk of acute in stent thrombosis.
27
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Case 2: Sepsis
Scenario
A confused 64-year-old male patient with a history of multiple myeloma who had received a cycle of antineoplastic therapy (bortezomib, dexamethasone) the previous day, was admitted to the ICU with septic fever, shivering, and circulatory shock. A several day old blunt trauma of the right forearm was seen during physical examination. Laboratory assessment indicated 
Management
The low platelet count could have been associated with the multiple myeloma and/or the antineoplastic therapy. However, considering the clinical context, the most likely reason was sepsis with an unknown focus. Further workup excluded the most frequent causes of sepsis, i.e. pneumonia (chest x-ray), urinary tract infections (urine stick) or peritonitis (sonography, physical examination). Infection of the wound at the right forearm injury was then assumed as the source of sepsis in this immunocompromised patient. After taking blood cultures and starting broad-spectrum antibiotics, surgical debridement was performed ( Figure 1B ), for which three therapeutic platelet concentrates (each containing 2-4x10 11 platelets/unit) were given prophylactically. The second prophylactic platelet transfusion was given five days later to allow surgical closure of the forearm wound.
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Comment
This case illustrates how important it is to identify and to control the source of sepsis to allow normalization of the coagulation system including the platelet count. Sepsis accounts for ≈ 50% of all thrombocytopenias in the severely ill. 17 The mechanisms leading to thrombocytopenia associated with sepsis are multifactorial and complex, and include decreased platelet production, increased platelet consumption as well as sequestration frequently by hemophagocytosis. 12 Enhanced platelet consumption results from ongoing thrombin generation and increased adhesion of platelets to endothelial cells. 17, 28 In critically ill septic patients, thrombocytopenia is associated with a dysregulated host response, 29,30 and it indicates poor prognosis in patients with septic shock.
31
Therapy of sepsis 32 requires source control, antibiotic therapy, and supportive measures. Platelet transfusion is recommended in case of bleeding platelet concentrates as part of the massive transfusion protocol, the platelet count rapidly declined during the first 7 hours after admission to 51x10 9 /L ( Figure 2 ).
Management
Traumatic bleeding from the pelvic arteries prompted embolization of the bleeding artery and subsequent retroperitoneal packing to control hemorrhage. In addition to massive transfusion (48 units RBCs, 22 units FFPs), fibrinogen was administered, as fibrinogen is the first coagulation factor that falls below critical values in the case of major bleeding 34 ( Figure   2 ). During the first four days, this patient was transfused with a total of 10 platelet concentrates (each 2-4x10 11 platelets/unit), mostly during (or shortly before) invasive procedures, with a targeted platelet count of >50x10 9 /L. The platelet count increased spontaneously, after bleeding was stopped by interventional and surgical procedures ( Figure   2 ).
Comment
Trauma-induced coagulopathy together with hemodilution due to massive transfusion of RBCs and FFPs 35 are common reasons for thrombocytopenia in the ICU. 17 In the presented case, severe trauma, massive bleeding (more than a two-fold loss of the blood volume), 34 and coagulopathy led to trauma-induced platelet loss and consumption. In addition, consumption of plasmatic coagulation factors, hyperfibrinolysis, and systemic inflammation 36 as well as hemodilution due to infusion of fluids and transfusion of blood products, and shock-related metabolic acidosis enhance the bleeding risk.
37
In actively bleeding trauma patients, transfusion of platelet concentrates alone will usually not stop bleeding, but this situation of consumptive coagulopathy is nevertheless an absolute indication for platelet transfusion as a bridging therapy to maintain the target platelet count until the surgeon or the interventionalist mechanically stops the bleeding. Current 
Management
We transfused 4 therapeutic units of platelet concentrates targeting a platelet count of >35x10 9 /L at admission and gave 1g IVIG/kg body weight per day for two days, together with 100mg prednisone during the first week. Platelet-inhibiting agents, e.g. non-steroidal anti-inflammatory drugs, were avoided and no routine heparin thromboprophylaxis was given. Repeated CT scans over the next days showed the brain contusions at a constant size, and the patient remained in a stable clinical condition.
However, on day 5 he developed symptomatic pulmonary embolism. At that time the 
In the absence of any laboratory or clinical symptoms for sepsis, heparin-induced thrombocytopenia (HIT) was first suspected in our patient. When we applied the 4Ts score 56 (Table 2 ) it revealed 4 points (platelet count decrease>50%=2 points; onset of platelet count fall >day 10=1 point; no thrombosis=0 point; thrombocytopenia in a patient on a ventilator as an assumed other reason for thrombocytopenia=1 point),
consistent with a an intermediate risk for HIT, but the anti-platelet factor (PF) 4/heparin IgG enzyme immunoassay was negative, thus ruling out HIT. 57, 58 On the other hand, valproic acid is known to cause both immune and non-immune mediated thrombocytopenia 59 (Table 3) . We stopped valproic acid while continuing all other medications, and the platelet count recovered ( Figure 3 ).
Comment
Drug-related thrombocytopenia is a relatively common cause of thrombocytopenia in ICU patients, 17 whereby non-immune drug-induced thrombocytopenia (DTP), e.g. caused by toxic bone marrow suppression, is responsible for the vast majority of cases. [60] [61] [62] [63] [64] [65] With the exception of HIT, drug-induced immune thrombocytopenia (DITP) is much less frequent than DTP. 17, 60, 64 In contrast to DTP, DITP typically presents with an abrupt platelet count fall evolving within one to two days, that begins usually 5 to 14 days after starting a new drug, and a nadir below 20x10 9 /L, nearly always accompanied by mucocutaneous bleeding.
59,65-69 Table 3 summarizes typical mechanisms and drugs of DTP and DITP.
More than 10% of patients treated with valproic acid develop DTP. 59 Older age, female sex, higher valproic acid dosage, and lower baseline platelet counts are associated with an increased risk for DTP. 59, 66, 67 However, valproic acid can also induce immune-mediated DITP. In both, DTP and DITP cessation of the drug is most important and usually sufficient. 59, [65] [66] [67] [68] [69] Recovery of the platelet count will occur thereafter and is often not very helpful for differentiation between DTP and DITP. In our patient the platelet count started to increase ≈ 48 hours after stopping valproic acid, but also in DITP platelet count recovery usually begins 5-7 half-times after cessation of the drug (half-time for valproic acid 5-7 hours = expected recovery after ≈ 50 hours). The relatively slow decline of the platelet count and especially the nadir above 20x10 9 /L argued against DITP.
If a patient with DITP develops major bleeding symptoms, IVIG (1g/kg body weight on two consecutive days) is recommended. 65 It augmented platelet count recovery in mouse models of DITP. 70 However, corticosteroids are usually ineffective. 65 In case of lifethreatening bleeding transfusion of platelet concentrates might be considered.
Laboratory tests for the detection of drug-dependent anti-platelet antibodies are helpful
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From to support the diagnosis DITP. 63 However, these tests are performed only in specialized laboratories and are usually not available to guide acute management. 71 In contrast to assays for detecting antibodies in HIT, the sensitivity of assays for all other DITPs is low and thus a negative test does not rule out the diagnosis. The clinical relevance of laboratory testing for DITP antibodies is twofold: first, it allows objective confirmation of an adverse drug effect (relevant for pharmacovigilance), and second it is important for the individual patient (future drug avoidance). We could not demonstrate valproic acid-dependent platelet-reactive antibodies in this patient, further supporting non-immune mechanisms. 
Comment
Analyzing carefully the platelet count course is helpful for discerning among various explanations for thrombocytopenia. Typically, ICU patients present with a biphasic platelet count course: After an initial decrease to a platelet count nadir 2 to 4 days after ICU admission, platelets recover to higher-than-baseline values (so-called reactive thrombocytosis 72 when the platelet count falls rapidly within 1-2 days during the second week of treatment, after an initial recovery.
Management
The initial platelet count fall was easily explained by the severe disease. However, when the platelets fell to <30x10 9 /L at day 5 we included HIT into the differential diagnoses of the low platelet count. The 4Ts score 56 was 4 points (2 points for the Thrombocytopenia, 1 point for the timing, 0 points for Thromboses, and 1 point for oTher reasons), giving an intermediate pretest probability of HIT. As in patients with a 4Ts score of ≥ 4 the probability of HIT is >25%, 56 we introduced alternative anticoagulation using danaparoid in prophylactic dose.
Because the suspicion of HIT was vague and the risk of bleeding high, we first used 
Comment
Even in hindsight, it is unclear whether the strong platelet-activating anti-PF4/heparin antibodies were really the cause of the low platelet count, or simply an epiphenomenon, as these antibodies are detected incidentally in some patients without thrombocytopenia, especially after cardiac surgery this may be the case in >10% of patients. 73, 74 However, the further worsening of thrombocytopenia 5 days after starting heparin, at a time when platelet count recovery would otherwise have been expected, together with a strongly-positive functional assay, prompted us to change anticoagulation to a non-heparin anticoagulant, given the risk for new thrombosis (up to 5% per day) in acute HIT, 75 
Platelet transfusions in ICU patients
A major issue in thrombocytopenic ICU patients is whether and when platelet transfusions should be given: 65 The same accounts for patients with acute HIT or thrombotic thrombocytopenic purpura (TTP). 84, 85 Due to the lack of prospective randomized trials major uncertainty exists in regard to Another issue is platelet transfusion before invasive procedures for which only observational studies exist. 
Autoantibodies
Production of platelet-specific autoantibodies is induced and maintained by a drug (exact mechanism unknown).
Procainamide, levodopa, gold
Prothrombotic
Heparin-induced thrombocytopenia
IgG antibodies against PF4/polyanion complexes activate platelets via the platelet Fc-receptor, inducing thrombin generation Heparin, low molecular weight heparin, potentially also other polyanionic drugs (e.g. aptamers)
Thrombotic microangiopathy
Auto-antibodies against ADAMTS13 are produced in presence of the drug causing ADAMTS13 deficiency. 
